NCT03082950

Brief Summary

HPV infections may be responsible for different types of cancer in females. Primary Goal of the study was to identify the prevalence of an hpv affiliation in retrospective-prospective analysed cohort of patients who suffer from vulvar cancer and their preinvasive lesions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2015

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

March 12, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 17, 2017

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2018

Completed
Last Updated

May 3, 2018

Status Verified

May 1, 2018

Enrollment Period

2.2 years

First QC Date

March 12, 2017

Last Update Submit

May 2, 2018

Conditions

Keywords

hpv prevalencerecurrence ratesurvival

Outcome Measures

Primary Outcomes (1)

  • prevalence of hpv infections among pations suffering from vulvar cancer and preinvasive lesions

    15yrs

Secondary Outcomes (1)

  • disease free survival among the groups

    15yrs

Study Arms (2)

1

human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions

Diagnostic Test: polymerase chain reaction

2

non-human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions

Diagnostic Test: polymerase chain reaction

Interventions

PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.

Also known as: EUROARRAY
12

Eligibility Criteria

Sexfemale(Gender-based eligibility)
Gender Eligibility Detailsfemale the illness only affiliates females
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

pts. who suffer from vulvar cancer and their preinvasive lesions who were treated in luebeck University medical Center over a 15 year period

You may qualify if:

  • pts. who suffer from vulvar cancer and their preinvasive lesions
  • positive informed consent
  • complete set of data
  • Treatment in luebeck university

You may not qualify if:

  • opposite of above

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Luebeck University, Department for obstetrics and gynecology

Lübeck, Schleswig-Holstein, D-23538, Germany

Location

Related Publications (3)

  • Massad LS, Jeronimo J, Katki HA, Schiffman M; National Institutes of Health/American Society for Colposcopy and Cervical Pathology Research Group. The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis. 2009 Jul;13(3):137-44. doi: 10.1097/LGT.0b013e31819308d4.

    PMID: 19550210BACKGROUND
  • Sri T, Merideth MA, Pulanic TK, Childs R, Stratton P. Human papillomavirus reactivation following treatment of genital graft-versus-host disease. Transpl Infect Dis. 2013 Aug;15(4):E148-51. doi: 10.1111/tid.12098. Epub 2013 May 28.

    PMID: 23710698BACKGROUND
  • Nocon M, Mittendorf T, Roll S, Greiner W, Willich SN, von der Schulenburg JM. Review on the medical and health economic evidence for an inclusion of colposcopy in primary screening programs for cervical cancer. GMS Health Technol Assess. 2007 Aug 10;3:Doc07.

    PMID: 21289941BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Tumor tissue samples are analyzed according to their hpv status

Study Officials

  • Daniel Beyer, MD

    Westpfalz-Klinikum

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
University of Luebeck

Study Record Dates

First Submitted

March 12, 2017

First Posted

March 17, 2017

Study Start

October 1, 2015

Primary Completion

December 1, 2017

Study Completion

May 1, 2018

Last Updated

May 3, 2018

Record last verified: 2018-05

Locations